Postoperative nausea and vomiting: translating pathophysiological mechanisms into clinical management Authors: Xin Zhao, Wenli Liao, Chen Chen, Yaru Zheng, Li Li, Quanyuan Chang, Lan Qiu, Jiang Shen Published: 2025 ABSTRACT Postoperative Nausea and Vomiting (PONV) is a potential complication in all people undergoing general anesthesia (GA), causing significant discomfort and potentially leading to serious complications. Despite decades of research and the implementation of various preventive drugs and measures, complete prevention via traditional guidelines continues to pose challenges in clinical settings. This article will review mechanisms, influencing factors (including patient-related, surgery-related, and anesthesia-related factors), and strategies for prevention and treatment, both pharmacological and non-pharmacological, for PONV in adultsunder GA. This manuscript also summarizes randomized trials investigating the incidence of PONV in adults receiving opioid-sparing or opioid-free perioperative GA-based protocols. This review aims to summarize evidence-based guidance amidst traditional guidance, and other recent considerations, for optimizing anesthetic management strategies in clinical practice. Introduction Postoperative nausea and vomiting (PONV) is a prevalent and distressing complication after surgery. Among adult patients undergoing general anesthesia (GA), the incidence varies, according to traditional consensus guidelines, between 30 and 80%, depending on legacy risk factors (Apfel et al. 1999; Gan 2006). In addition to causing discomfort to patients, PONV also delays the intake of fluids and food after surgery, a problem which is then superimposed on postoperative pain, both complicating the patient's recovery. In severe instances, PONV may result in complications such as wound dehiscence, electrolyte imbalances, intracranial hypertension, and aspiration pneumonia. These adverse events collectively prolong hospital stays and escalate healthcare expenditures and readmission risks, while diminishing patient satisfaction with surgical care(Eberhart et al. 2002; Gold et al. 1989; Hocking et al. 2013). With heightened clinical awareness of PONV in recent years, its management is now considered equally essential as controlling postoperative pain, and in some situations, it may require even higher priority. This review examines the causes, risk factors, and strategies for preventing and treating PONV in patients who receive GA, with the aim of improving patient outcomes, care quality, and cost containment. Pathogenesis of PONV PONV arises from multiple contributing factors and involves complex biological processes. Despite extensive research, the exact mechanisms behind this symptom remains incompletely understood. Nausea, a distressing subjective experience accompanied by the urge to vomit, is thought to be caused by hyperactivation of central neural pathways associated with conscious arousal (Kenward et al. 2015). A variety of neurotransmitters and hormones are associated with nausea, with research indicating that cortisol, norepinephrine, vasopressin, 5-hydroxytryptamine (5-HT), substance P, and the nonapeptide oxytocin(Boulet et al. 2016) contribute to nausea(Kenward et al. 2015). Vomiting is the act of intense clearance of gastrointestinal contents, serving as a defense mechanism for the body. Intestinal chromaffin cells in gastrointestinal (GI) mucosa, enteric nervous system, vagus, and splanchnic nerves are key sites for peripherally mediated vomiting (Zhong et al. 2021). The control center for vomiting is located in the brainstem, primarily mediated by the DVC – an anatomical entity formed by three components: the area postrema(AP), the NTS, and the dorsal motor nucleus of the vagus (DMV) (Kenward et al. 2015). AP and NTS are the main central receptors for peripheral emetic stimulation, and respond quickly to various emetic substances (toxins, metabolites, or drugs) in the blood and cerebrospinal fluid (Wickham 2020). Their signal transduction is mainly mediated by the neurotransmitter receptor system. The main receptors involved are dopamine, 5-HT, neurokinin-1(NK1), acetylcholine, histamine, and opioid, along with others (Zhong et al. 2021). NTS also receives direct or indirect afferent nerve impulses from AP and peripheral receptors; NTS also plays a key role in the central regulation of the vomiting reflex(Sanger And Andrews 2006; Gagliuso et al. 2019; Babic And Browning 2014; Spiegel et al. 2017; Darmani And Ray 2009). DMV transmits the movement of vagal fibers, receives the signals from NTS, and mediates GI movement during vomiting (Darmani And Ray 2009; Bashashati And McCallum 2014; Travagli et al. 2006). PONV risk factors Risk factors related to PONV in adults include three aspects: patient-related, surgery-related, and anesthesia-related. Patient- related factors Studies by Burtles and Peckett. (1957) and Bellville et al. (1960) in the 1960 s published a number of factors, including age, sex, motion sickness or history of PONV using a cross-classification method. Later studies gradually applied logistic regression analysis and identified risk factors including non-smoking history, preoperative fasting, and menstrual cycle (Apfel et al. 1999; Koivuranta et al. 1997; Apfel et al. 2012). Among these, female gender, nonsmoking status, motion sickness or a history of PONV, and younger age were confirmed as the most significant risk factors for PONV and the key patient-specific predictors (Apfel et al. 1999; Koivuranta et al. 1997; Apfel et al. 2012; Gan et al. 2007). In addition, studies have suggested that Body Mass Index(BMI), American Society of Anesthesiologists(ASA) physical status rating, preoperative anxiety, nausea and/or vomiting unrelated to a perioperative experience, and migraine may be associated with the development of PONV (Torres et al. 2015; Stadler et al. 2003; Van den Bosch et al. 2005). Surgery-related factors Surgical tissue injury and inflammation can trigger localized release of inflammatory mediators including substance P, tumor necrosis factor-alpha (TNF-α), 5-HT, and interleukin-6 (IL-6) (Spiller 2008).This process may upregulate intestinal 5-HT expression, potentially enhancing excitability of the mesenteric plexus and vagus nerve, thereby contributing to the development of PONV. The impact of the surgical site and approach on PONV varies significantly. Studies suggest that cholecystectomy, laparoscopic surgery, gynecological surgery, abdominal surgery, maxillofacial surgery, ophthalmic surgery and neurosurgery may increase the occurrence of PONV (Gan et al. 2007; Wang et al. 2000; Chatterjee et al. 2011; Matthews 2017; Gan et al. 2020). At the same time, the duration of surgery also impacts PONV risk (Gan et al. 2007), with the risk of PONV increasing by 60% for every additional 30 min of surgery. Anesthesia-related factors Sinclair et al. (Sinclair et al. 1999) found that patients who received GA were 9 times more likely to develop PONV compared to those who received local anesthesia, and that this increased risk was mainly related to the anesthetic drugs used during GA. Opioids Opioids are primarily employed for perioperative analgesia due to their efficacy in suppressing surgical stress responses, maintaining an irreplaceable role as the most widely used drugs in general anesthesia. However, animal studies have shown that opioids can directly stimulate AP and NTS, thereby provoking the onset of PONV (Chen et al. 2003). At the same time, opioids can stimulate the μ receptors in the gastrointestinal tract, inhibiting the release of acetylcholine from the mesenteric plexus. This reduces smooth muscle tension and peristalsis, leading to gastric dilation and delayed gastric emptying. These pathophysiological changes thus activate visceral mechanoreceptors and chemoreceptors, which transmit nausea and vomiting signals to the central nervous system (Apfel et al. 2012). Therefore, the use of opioids after surgery has been listed by many researchers as one of the independent risk factors for predicting PONV. The dose-dependent effect of opioids on PONV is well-established (Roberts et al. 2005). Theoretically, reducing perioperative opioid consumption could decrease the risk of PONV. It is well known that general anesthesia combined with regional nerve block or intraspinal anesthesia/analgesia can effectively reduce the dosage of opioids. In addition, studies have confirmed that the use of dexmedetomidine (Singh et al. 2017; Blaudszun et al. 2012), ketamine (Elia and Tramèr 2005), nonsteroidal anti-inflammatory drugs (NSAIDs) (Elia et al. 2005; Marret et al. 2005), lidocaine, magnesium sulfate and other drugs can reduce perioperative opioid consumption. The effects of different types of surgery and different opioid reduction regimens on PONV are also different. We systematically collated randomized controlled clinical trials (RCTs) from the PubMed database that have investigated perioperative opioid-reduction or opioid-free strategies in adults under GA, excluding those solely combining neuraxial anesthesia or regional nerve blocks. According to the timing of the intervention (e.g., preoperative, intraoperative), each study is listed in Tables 1, 2, 3, 4 and 5, with each table arranged in descending order of the publication year of the articles. The references cited in the table can be found in Supplementary Materials. Recent evidence indicates that opioid-free anesthesia (OFA), as part of enhanced recovery after surgery (ERAS) pathways, slightly decreases PONV incidence and antiemetic use (Apfel et al. 2002; Murakawa et al. 1994; Divatia et al. 1996; Nader et al. 2004; Hase et al. 2019; Machu And Harris 1994).Table 1List of randomized controlled clinical studies- PreoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONV Tavanaei et al. (2024)26Posterolateral lumbar fusion and internal fixationMs, PrIsofluraneNo + Tavanaei et al. (2024)26Posterolateral lumbar fusion and internal fixationPrIsofluraneNo + Tavanaei et al. (2024)26Posterolateral lumbar fusion and internal fixationMsIsofluraneNo ± Zhou et al. (2023b)37Total knee replacementPr, NcNot provideNo + Zhou et al. (2023b)38Total knee replacementPrNot provideNo + Zhou et al. (2023b)38Total knee replacementNcNot provideNo + Zeng et al. (2019)61Suboccipital or subtemporal approach craniotomyGaPropofolNo + Salah Abdelgalil et al. (2019)30Open chest surgery (lung or pleural cancer)Pr, MsSevofluraneNo + Salah Abdelgalil et al. (2019)30Open chest surgery (lung or pleural cancer)PrSevofluraneNo + Salah Abdelgalil et al. (2019)30Open chest surgery (lung or pleural cancer)MsSevofluraneNo + Mardani-Kivi et al. (2016)38Bankart arthroscopic surgeryGaNitrous oxide, IsofluraneNo ± Ahiskalioglu et al. (2016)20Orthognathic SurgeryPrNitrous oxide, SevofluraneNo + Ajori et al. (2012)70Transabdominal hysterectomy (benign lesions)GaNitrous oxide, IsofluraneNo + Moon et al. (2011)38Transabdominal hysterectomyNcNitrous oxide, SevofluraneNo + Cabrera Schulmeyer et al. (2010)40Laparoscopic sleeve gastrectomyNcIsofluraneNo + Menda et al. (2010)30Coronary artery bypass surgery (male)GaPropofolNo + Srivastava et al. (2010)60Minilap open cholecystectomyGaNitrous oxide, HalothaneNo + Sapolya et al. (2007)25Abdominal hysterectomyNcNitrous oxide, SevofluraneNo + Puura et al. (2006)25Laparoscopic cholecystectomyNcSevofluraneNo ± Rorarius et al. (2004)45Transvaginal hysterectomyGaSevofluraneNo + Turan et al. (2004)25Transabdominal hysterectomyGaNitrous oxide, SevofluraneNo + Karamanloğlu et al. (2004)30Abdominal hysterectomyNcNitrous oxide, SevofluraneNo ± Ng et al. (2003)24Transabdominal hysterectomyNcNitrous oxide, Isoflurane, PropofolNo ± Recart et al. (2003)63Minor ear-nose-throat surgeryNcDesfluraneNo ± Reuben et al. (2002)25Outpatient laparoscopic tubal ligationOcNitrous oxide, IsofluraneNo + Alexander et al. (2002)34Hip and knee replacementNcNitrous oxide, IsofluraneNo + Hovorka et al. (1993)85Cesarean section under general anesthesiaNcNitrous oxide, HalothaneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effectTable 2List of randomized controlled clinical studies- Preoperative and Intraoperative/Preoperative and postoperative/Preoperative and Intraoperative and postoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONVPreoperative and Intraoperative Zhang et al. (2024)101Thoracoscopic surgeryDt, Lc, RbPropofolNo ± Kim et al. (2014)25Laminectomy or discectomy (1 segment)LcNitrous oxide, SevofluraneNo ± Yon et al. (2014)18Subtotal gastrectomyLcNitrous oxide, DesfluraneNo ± Soliman et al. (2011)20craniotomy for supratentorial tumorsDtSevofluraneNo + Preoperative and postoperative Zhang et al. (2024)50Elective craniotomy(intraoperative awakening)PrPropofolNo + Bekawi et al. (2014)30Laparoscopic cholecystectomyPreIsofluraneNo + Blumenthal et al. (2007)20Lumbar discectomyOcPropofolNo + Ma et al. (2004)30Inguinal hernia repairNcNitrous oxide, PropofolNo ± Dierking et al. (2004)40Transabdominal hysterectomyGaPropofolNo ± Watcha et al. (2003)60Outpatient otolaryngologic surgeryNcDesfluraneNo ± Preoperative, Intraoperative and Postoperative Recart et al. (2005)15Unilateral laparoscopic nephrectomyNc, RbDesfluraneNo + Koppert et al. (2004)20Major abdominal surgeryLcNitrous oxide, IsofluraneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effectTable 3List of randomized controlled clinical studies- Intraoperative and PostoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONV Qi et al. (2024)210Thoracoscopic lobectomyEsPropofolYes + Tejedor et al. (2023)20Tumor reduction surgeryEsSevofluraneNo + Chen et al. (2023a)39Laparoscopic hysterectomyDt, Es, RbPropofolNo + Plass et al. (2021)89Laparoscopic weight loss surgeryLcDesfluraneNo ± Tao et al. (2019)-Laparoscopic gynecological surgeryOcSevofluraneYes + Minoshima et al. (2015)17Adolescent idiopathic posterior scoliosis correction surgeryKtPropofolNo + Sridhar et al. (2015)67Open abdominal surgeryLcNot provideNo + Song et al. (2013)25Posterior lumbar fusion surgery (segments 1–2)KtSevofluraneYes ± Farag et al. (2013)58Multilevel spinal surgeryLcSevofluraneNo ± Yazar et al. (2011)30Lumbar discectomyNcNitrous oxide, SevofluraneNo + McKay et al. (2009)34Outpatient surgeryLcNot provideNo ± Zakine et al. (2008)27Major abdominal, urinary, or vascular surgeryKtNitrous oxide, DesfluraneNo + Govindarajan et al. (2005)25Laparoscopic gastric bypass surgeryNcNitrous oxide, DesfluraneNo + Adam et al. (2005)20Total knee replacementKtNitrous oxide, SevofluraneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effectTable 4List of randomized controlled clinical studies- IntraoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONV Wang et al. (2024)197Thyroid and parathyroid surgeryDt, Lc, EsPropofolYes + Barakat et al. (2024)24Spinal fusion surgeryDt, LcPropofol, SevofluraneNo + Li et al. (2024)46ThyroidectomyLc, EsPropofolNo + Rv et al. (2024)44Laparoscopic cholecystectomyDt, EsSevofluraneNo + Bao et al. (2024)86Thoracoscopic pneumonectomyDt, Lc, MsPropofolYes ± Clanet et al. (2024)86Laparoscopic gastric bypass surgeryDt, Lc, Es, MsSevofluraneNo + Feng et al. (2024)60Thoracoscopic pneumonectomyDt, EsSevofluraneYes + Si et al. (2024)60Conization of cervixEsPropofolNo ± Hao et al. (2023)40Laparoscopic cholecystectomyDt, EsPropofolNo + Liu et al. (2023)38Thyroid surgeryDt, Lc, Es, RbPropofolYes + Yu et al. (2023)50Laparoscopic cholecystectomyDt, Lc, Es, RbSevofluraneNo ± Qian et al. (2023)40lumpectomyDt, Lc, EsPropofolNo + Chen et al. (2023b)42Thoracoscopic pneumonectomyEsPropofolNo ± Zhou et al. (2023c)388Endoscopic sinus surgeryDt, Lc, EsPropofol, SevofluraneNo + Mieszczański et al. (2023)30Laparoscopic sleeve gastrectomyDt, Lc, Es, MsDesfluraneNo + Hs et al. (2023)24Endoscopic sinus surgery and septoplastyDt, LcSevofluraneNo + Naik et al. (2023)64Breast Cancer SurgeryEsNot provideYes + Yurttas et al. (2023)70Weight-loss surgeryLcPropofolNo ± Ma et al. (2023)36Benign laparoscopic gynecological surgeryEsPropofolNo + Zhang et al. (2023)34Modified radical mastectomyEsPropofolNo + Cha et al. (2023)45HysteroscopyLcSevofluraneNo + Khalil et al. (2023)30Laparoscopic sleeve gastrectomyDtSevofluraneNo + Khalil et al. (2023)30Laparoscopic sleeve gastrectomyEsSevofluraneNo ± Toleska et al. (2023)20Open colorectal surgeryLc, Es, Ms, RbSevofluraneNo + Wang et al. (2022)40Thoracoscopic surgeryDt, Lc, RBPropofol, SevofluraneNo ± Toleska et al. (2022)40Laparoscopic cholecystectomyLc, Kt, MsSevofluraneYes ± Zhu et al. (2022)47Hysteroscopy and cervical conization day surgeryEsPropofolYes + Nam et al. (2022)67Laparoscopic weight loss surgeryDtPropofolYes + Sharma et al. (2022)35laparoscopic intraperitoneal onlay mesh repairLcNitrous oxide, SevofluraneNo ± An et al. (2022)51Laparoscopic radical colectomyDtSevofluraneNo ± Chen et al. (2022)39Laparoscopic gynecological surgeryDt, LcPropofolNo + Elshafie et al. (2022)20Liver resection for cirrhosisDt, Lc, Ms, RbSevofluraneNo + Massoth et al. (2021)76Gynecologic laparoscopyDt, EsSevofluraneYes ± Benedetto et al. (2021)38Quadrantectomy for breast cancerKt, MsDesflurane, PropofolNo + Xu et al. (2021)62Laparoscopic hysterectomyDt, LcPropofolYes + Beloeil et al. (2021)156Major or intermediate noncardiac surgeryDt, Lc, cDesfluraneNo + Seppänen et al. (2021)75Total knee replacementDtPropofolNo ± Mulier et al. (2021)102Deep inferior epigastric perforator flap surgeryDt, Lc, KtSevoflurane, PropofolNo + Wang et al. (2021)50Upper respiratory tract SurgeryLcPropofolNo + Hakim and Wahba (2019)40Ambulatory gynecological laparoscopic surgeryDtPropofolNo + Liu et al. (2018)30Thoracoscopic lobectomyLcPropofolNo + Li et al. (2016)30Lumbar decompression fusion internal fixation surgeryDtNitrous oxide, PropofolNo + Song et al. (2016)30Supratentorial craniotomyDtPropofolNo ± García-Navia et al. (2016)11Gynecologic open surgeryLcPropofolNo + García-Navia et al. (2016)11Gynecologic open surgeryKtPropofolNo + Bakan et al. (2015)40Laparoscopic cholecystectomyDt, LcPropofolNo + Hwang et al. (2015)40Posterior lumbar interbody fusionDtPropofolNo + Ziemann-Gimmel et al. (2014)60Bariatric surgeryDt, KtSevofluraneYes + Gharaei et al. (2013)95Extracorporeal lithotripsy of upper one-third kidney or ureteral stones in opioid abusersKtNot provideNo ± Ryu et al. (2009)40Middle ear surgeryMsSevofluraneNo + Turgut et al. (2008)25Lumbar laminectomyDtPropofolNo + Tufanogullari et al. (2008)20Laparoscopic weight loss SurgeryDtDesfluraneNo + Aveline et al. (2006)23Lumbar DiscectomyKtNitrous oxide, SevofluraneNo + Guignard et al. (2002)25Open colorectal surgeryKtDesfluraneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effectTable 5List of randomized controlled clinical studies-PostoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONV Koo et al. (2024)43Microvascular decompressionNcPropofolYes + Dong et al. (2017)49Thoracotomy surgeryDtPropofol, SevofluraneNo + Wang et al. (2016)20Laparoscopic surgery for endometrial or cervical cancerDtPropofol, SevofluraneNo + Lin et al. (2009)50Transabdominal total hysterectomyDtNitrous oxide, IsofluraneNo + Freedman and O'Hara (2008)40Smooth shell saline breast prosthesis submuscular augmentationPrPropofolNo + Kollender et al. (2008)28Surgery for bone and soft tissue tumorsKtNitrous oxide, IsofluraneNo + Koç et al. (2007)20Surgery for varicoceleGaNitrous oxide, PropofolNo + Kemal et al. (2007)20Transabdominal gynecological surgery (myomectomy, total hysterectomy)NcNitrous oxide, SevofluraneNo + Hynninen et al. (2000)30Coronary artery bypass graftingNcPropofol, IsofluraneNo ± Powell et al. (1990)40Transabdominal gynecological surgeryNcNitrous oxide, Halothane, or IsofluraneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect Table 1List of randomized controlled clinical studies- PreoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONV Tavanaei et al. (2024)26Posterolateral lumbar fusion and internal fixationMs, PrIsofluraneNo + Tavanaei et al. (2024)26Posterolateral lumbar fusion and internal fixationPrIsofluraneNo + Tavanaei et al. (2024)26Posterolateral lumbar fusion and internal fixationMsIsofluraneNo ± Zhou et al. (2023b)37Total knee replacementPr, NcNot provideNo + Zhou et al. (2023b)38Total knee replacementPrNot provideNo + Zhou et al. (2023b)38Total knee replacementNcNot provideNo + Zeng et al. (2019)61Suboccipital or subtemporal approach craniotomyGaPropofolNo + Salah Abdelgalil et al. (2019)30Open chest surgery (lung or pleural cancer)Pr, MsSevofluraneNo + Salah Abdelgalil et al. (2019)30Open chest surgery (lung or pleural cancer)PrSevofluraneNo + Salah Abdelgalil et al. (2019)30Open chest surgery (lung or pleural cancer)MsSevofluraneNo + Mardani-Kivi et al. (2016)38Bankart arthroscopic surgeryGaNitrous oxide, IsofluraneNo ± Ahiskalioglu et al. (2016)20Orthognathic SurgeryPrNitrous oxide, SevofluraneNo + Ajori et al. (2012)70Transabdominal hysterectomy (benign lesions)GaNitrous oxide, IsofluraneNo + Moon et al. (2011)38Transabdominal hysterectomyNcNitrous oxide, SevofluraneNo + Cabrera Schulmeyer et al. (2010)40Laparoscopic sleeve gastrectomyNcIsofluraneNo + Menda et al. (2010)30Coronary artery bypass surgery (male)GaPropofolNo + Srivastava et al. (2010)60Minilap open cholecystectomyGaNitrous oxide, HalothaneNo + Sapolya et al. (2007)25Abdominal hysterectomyNcNitrous oxide, SevofluraneNo + Puura et al. (2006)25Laparoscopic cholecystectomyNcSevofluraneNo ± Rorarius et al. (2004)45Transvaginal hysterectomyGaSevofluraneNo + Turan et al. (2004)25Transabdominal hysterectomyGaNitrous oxide, SevofluraneNo + Karamanloğlu et al. (2004)30Abdominal hysterectomyNcNitrous oxide, SevofluraneNo ± Ng et al. (2003)24Transabdominal hysterectomyNcNitrous oxide, Isoflurane, PropofolNo ± Recart et al. (2003)63Minor ear-nose-throat surgeryNcDesfluraneNo ± Reuben et al. (2002)25Outpatient laparoscopic tubal ligationOcNitrous oxide, IsofluraneNo + Alexander et al. (2002)34Hip and knee replacementNcNitrous oxide, IsofluraneNo + Hovorka et al. (1993)85Cesarean section under general anesthesiaNcNitrous oxide, HalothaneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect List of randomized controlled clinical studies- Preoperative Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect Table 2List of randomized controlled clinical studies- Preoperative and Intraoperative/Preoperative and postoperative/Preoperative and Intraoperative and postoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONVPreoperative and Intraoperative Zhang et al. (2024)101Thoracoscopic surgeryDt, Lc, RbPropofolNo ± Kim et al. (2014)25Laminectomy or discectomy (1 segment)LcNitrous oxide, SevofluraneNo ± Yon et al. (2014)18Subtotal gastrectomyLcNitrous oxide, DesfluraneNo ± Soliman et al. (2011)20craniotomy for supratentorial tumorsDtSevofluraneNo + Preoperative and postoperative Zhang et al. (2024)50Elective craniotomy(intraoperative awakening)PrPropofolNo + Bekawi et al. (2014)30Laparoscopic cholecystectomyPreIsofluraneNo + Blumenthal et al. (2007)20Lumbar discectomyOcPropofolNo + Ma et al. (2004)30Inguinal hernia repairNcNitrous oxide, PropofolNo ± Dierking et al. (2004)40Transabdominal hysterectomyGaPropofolNo ± Watcha et al. (2003)60Outpatient otolaryngologic surgeryNcDesfluraneNo ± Preoperative, Intraoperative and Postoperative Recart et al. (2005)15Unilateral laparoscopic nephrectomyNc, RbDesfluraneNo + Koppert et al. (2004)20Major abdominal surgeryLcNitrous oxide, IsofluraneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect List of randomized controlled clinical studies- Preoperative and Intraoperative/Preoperative and postoperative/Preoperative and Intraoperative and postoperative Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect Table 3List of randomized controlled clinical studies- Intraoperative and PostoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONV Qi et al. (2024)210Thoracoscopic lobectomyEsPropofolYes + Tejedor et al. (2023)20Tumor reduction surgeryEsSevofluraneNo + Chen et al. (2023a)39Laparoscopic hysterectomyDt, Es, RbPropofolNo + Plass et al. (2021)89Laparoscopic weight loss surgeryLcDesfluraneNo ± Tao et al. (2019)-Laparoscopic gynecological surgeryOcSevofluraneYes + Minoshima et al. (2015)17Adolescent idiopathic posterior scoliosis correction surgeryKtPropofolNo + Sridhar et al. (2015)67Open abdominal surgeryLcNot provideNo + Song et al. (2013)25Posterior lumbar fusion surgery (segments 1–2)KtSevofluraneYes ± Farag et al. (2013)58Multilevel spinal surgeryLcSevofluraneNo ± Yazar et al. (2011)30Lumbar discectomyNcNitrous oxide, SevofluraneNo + McKay et al. (2009)34Outpatient surgeryLcNot provideNo ± Zakine et al. (2008)27Major abdominal, urinary, or vascular surgeryKtNitrous oxide, DesfluraneNo + Govindarajan et al. (2005)25Laparoscopic gastric bypass surgeryNcNitrous oxide, DesfluraneNo + Adam et al. (2005)20Total knee replacementKtNitrous oxide, SevofluraneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect List of randomized controlled clinical studies- Intraoperative and Postoperative Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect Table 4List of randomized controlled clinical studies- IntraoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONV Wang et al. (2024)197Thyroid and parathyroid surgeryDt, Lc, EsPropofolYes + Barakat et al. (2024)24Spinal fusion surgeryDt, LcPropofol, SevofluraneNo + Li et al. (2024)46ThyroidectomyLc, EsPropofolNo + Rv et al. (2024)44Laparoscopic cholecystectomyDt, EsSevofluraneNo + Bao et al. (2024)86Thoracoscopic pneumonectomyDt, Lc, MsPropofolYes ± Clanet et al. (2024)86Laparoscopic gastric bypass surgeryDt, Lc, Es, MsSevofluraneNo + Feng et al. (2024)60Thoracoscopic pneumonectomyDt, EsSevofluraneYes + Si et al. (2024)60Conization of cervixEsPropofolNo ± Hao et al. (2023)40Laparoscopic cholecystectomyDt, EsPropofolNo + Liu et al. (2023)38Thyroid surgeryDt, Lc, Es, RbPropofolYes + Yu et al. (2023)50Laparoscopic cholecystectomyDt, Lc, Es, RbSevofluraneNo ± Qian et al. (2023)40lumpectomyDt, Lc, EsPropofolNo + Chen et al. (2023b)42Thoracoscopic pneumonectomyEsPropofolNo ± Zhou et al. (2023c)388Endoscopic sinus surgeryDt, Lc, EsPropofol, SevofluraneNo + Mieszczański et al. (2023)30Laparoscopic sleeve gastrectomyDt, Lc, Es, MsDesfluraneNo + Hs et al. (2023)24Endoscopic sinus surgery and septoplastyDt, LcSevofluraneNo + Naik et al. (2023)64Breast Cancer SurgeryEsNot provideYes + Yurttas et al. (2023)70Weight-loss surgeryLcPropofolNo ± Ma et al. (2023)36Benign laparoscopic gynecological surgeryEsPropofolNo + Zhang et al. (2023)34Modified radical mastectomyEsPropofolNo + Cha et al. (2023)45HysteroscopyLcSevofluraneNo + Khalil et al. (2023)30Laparoscopic sleeve gastrectomyDtSevofluraneNo + Khalil et al. (2023)30Laparoscopic sleeve gastrectomyEsSevofluraneNo ± Toleska et al. (2023)20Open colorectal surgeryLc, Es, Ms, RbSevofluraneNo + Wang et al. (2022)40Thoracoscopic surgeryDt, Lc, RBPropofol, SevofluraneNo ± Toleska et al. (2022)40Laparoscopic cholecystectomyLc, Kt, MsSevofluraneYes ± Zhu et al. (2022)47Hysteroscopy and cervical conization day surgeryEsPropofolYes + Nam et al. (2022)67Laparoscopic weight loss surgeryDtPropofolYes + Sharma et al. (2022)35laparoscopic intraperitoneal onlay mesh repairLcNitrous oxide, SevofluraneNo ± An et al. (2022)51Laparoscopic radical colectomyDtSevofluraneNo ± Chen et al. (2022)39Laparoscopic gynecological surgeryDt, LcPropofolNo + Elshafie et al. (2022)20Liver resection for cirrhosisDt, Lc, Ms, RbSevofluraneNo + Massoth et al. (2021)76Gynecologic laparoscopyDt, EsSevofluraneYes ± Benedetto et al. (2021)38Quadrantectomy for breast cancerKt, MsDesflurane, PropofolNo + Xu et al. (2021)62Laparoscopic hysterectomyDt, LcPropofolYes + Beloeil et al. (2021)156Major or intermediate noncardiac surgeryDt, Lc, cDesfluraneNo + Seppänen et al. (2021)75Total knee replacementDtPropofolNo ± Mulier et al. (2021)102Deep inferior epigastric perforator flap surgeryDt, Lc, KtSevoflurane, PropofolNo + Wang et al. (2021)50Upper respiratory tract SurgeryLcPropofolNo + Hakim and Wahba (2019)40Ambulatory gynecological laparoscopic surgeryDtPropofolNo + Liu et al. (2018)30Thoracoscopic lobectomyLcPropofolNo + Li et al. (2016)30Lumbar decompression fusion internal fixation surgeryDtNitrous oxide, PropofolNo + Song et al. (2016)30Supratentorial craniotomyDtPropofolNo ± García-Navia et al. (2016)11Gynecologic open surgeryLcPropofolNo + García-Navia et al. (2016)11Gynecologic open surgeryKtPropofolNo + Bakan et al. (2015)40Laparoscopic cholecystectomyDt, LcPropofolNo + Hwang et al. (2015)40Posterior lumbar interbody fusionDtPropofolNo + Ziemann-Gimmel et al. (2014)60Bariatric surgeryDt, KtSevofluraneYes + Gharaei et al. (2013)95Extracorporeal lithotripsy of upper one-third kidney or ureteral stones in opioid abusersKtNot provideNo ± Ryu et al. (2009)40Middle ear surgeryMsSevofluraneNo + Turgut et al. (2008)25Lumbar laminectomyDtPropofolNo + Tufanogullari et al. (2008)20Laparoscopic weight loss SurgeryDtDesfluraneNo + Aveline et al. (2006)23Lumbar DiscectomyKtNitrous oxide, SevofluraneNo + Guignard et al. (2002)25Open colorectal surgeryKtDesfluraneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect List of randomized controlled clinical studies- Intraoperative Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect Table 5List of randomized controlled clinical studies-PostoperativeLiteratureNType of surgeryOpioid-free or opioid-reduced measuresAnesthesia maintenanceWhether PONV is the primary outcomeEffect on PONV Koo et al. (2024)43Microvascular decompressionNcPropofolYes + Dong et al. (2017)49Thoracotomy surgeryDtPropofol, SevofluraneNo + Wang et al. (2016)20Laparoscopic surgery for endometrial or cervical cancerDtPropofol, SevofluraneNo + Lin et al. (2009)50Transabdominal total hysterectomyDtNitrous oxide, IsofluraneNo + Freedman and O'Hara (2008)40Smooth shell saline breast prosthesis submuscular augmentationPrPropofolNo + Kollender et al. (2008)28Surgery for bone and soft tissue tumorsKtNitrous oxide, IsofluraneNo + Koç et al. (2007)20Surgery for varicoceleGaNitrous oxide, PropofolNo + Kemal et al. (2007)20Transabdominal gynecological surgery (myomectomy, total hysterectomy)NcNitrous oxide, SevofluraneNo + Hynninen et al. (2000)30Coronary artery bypass graftingNcPropofol, IsofluraneNo ± Powell et al. (1990)40Transabdominal gynecological surgeryNcNitrous oxide, Halothane, or IsofluraneNo ± Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect List of randomized controlled clinical studies-Postoperative Dt Dexmedetomidine, Lc Lidocaine, Kt Ketamine, Es Esketamine, Oc Oxycodone, Ms Magnesium sulfate, Rb Regional nerve block, Ga Gabapentin, Pr Pregabalin, = NSAIDs/COX-2's, PONV = postoperative nausea and vomiting + : favorable, ± : No effect Inhalational anesthetics Inhalational anesthetics, including nitrous oxide(N2O) and volatile anesthetics (isoflurane, sevoflurane, desflurane), are accepted as a main cause of PONV in the early postoperative period (0-2h) (Apfel et al. 2002). The incidence of PONV in patients receiving inhalational anesthetics was 1.82 times higher than that of other drugs 2–6 h after surgery (Gan et al. 2020). PONV induced by N2O may be related to its action on central dopamine receptors and opioid receptors (Murakawa et al. 1994; Divatia et al. 1996), alteration of middle ear pressure (Nader et al. 2004), and/or dilation of gastrointestinal tract (Divatia et al. 1996). In vitro experiments showed that volatile agents can increase the expression of c-Fos (a neuronal activation marker) in the area postrema of rats (Hase et al. 2019), while enhancing the function of 5-HT3 receptor in Xenopus laevis oocytes (Machu And Harris 1994), which may respectively be causes of PONV. In addition, the dose of inhalational anesthetics is positively correlated with the occurrence of PONV (Apfel et al. 2002). Therefore, some authorities endorse avoidance of inhaled anesthetics in patients at high risk of PONV (Gan et al. 2020; Apfel et al. 2002). Intravenous anesthetics Propofol is a commonly used intravenous anesthetic that acts at the cortical tract of the vomiting center; propofol is thought to have a protective effect against PONV. Studies have found that compared with inhaled anesthesia, total intravenous anesthesia (TIVA) combined with propofol can reduce the risk of PONV (Elbakry et al. 2018; Schaefer et al. 2016; Lee et al. 2015). A randomized trial demonstrated that in female patients undergoing thyroid surgery, propofol significantly reduced the incidence of PONV when compared to desflurane: there was a statistically significant advantage in the post-anesthesia care unit (PACU) stage (2.6% vs. 18.4%; P < 0.05) and 24 h after surgery (44.7% vs. 68.4%; P < 0.05). Moreover, the propofol group did not require additional antiemetic drugs during the PACU period, while 5 patients (13.2%) in the desflurane group required additional interventions (Hase et al. 2019). Another study found that infusion of subhypnotic propofol combined with antiemetics could significantly reduce the incidence of PONV (Erdem et al. 2008, 2009), but the effect was short-lived, and the PONV recurrence rate was high. Dexmedetomidine, an alpha2 adrenergic receptor agonist, reduces the occurrence of PONV by decreasing the production of norepinephrine. Administration of dexmedetomidine at 1 μg/kg before surgery not only reduces pain after laparoscopic cholecystectomy but also reduces the incidence of PONV, with an effect not statistically differing from that of intravenous dexamethasone 8 mg (21% vs. 28%; P > 0.05) (Bakri et al. 2015). Remimazolam is a new benzodiazepine. It can replace propofol for anesthesia and sedation in short surgery, day surgery, and outpatient surgery due to its rapid onset, no accumulation, and little effect on respiration and circulation. However, the incidence of PONV with remimazolam is higher than that with propofol. Recent evidence ‌ suggests that use of its antagonist flumazenil during gynecological day surgery may increase the risk of PONV within 24 h after surgery. An observational study of 141 patients showed a significantly higher incidence of PONV in the flumazenil group than in the control group (50.7% vs. 32.9%; P < 0.05) (Wei et al. 2024). Other intravenous anesthetics, such as ketamine, etomidate, and thiopental have been suggested to increase the risk of PONV. However, the results of the latest meta-analysis show that perioperative use of ketamine or esketamine (pure dextro-isomer of ketamine) does not increase the risk of PONV, while providing analgesia/anti-hyperalgesia, improving psychological status, and promoting other aspects of recovery in the early postoperative period (Hung et al. 2024). Muscle relaxant antagonists Although non-depolarizing muscle relaxants have no effect on PONV, their antagonist neostigmine may contribute to PONV (Tramèr And Fuchs-Buder 1999; Hood et al. 1995; Paech et al. 2018), with higher doses of neostigmine (> 2.5 mg/70 kg) being associated with an increased need for rescue antiemetics (Azimaraghi et al. 2023). In contrast to neostigmine, recently-introduced steroidal muscle relaxant antagonist sugammadex improves PONV, and is significantly associated with a lower incidence of PONV in the early postoperative period (Ju et al. 2023). A multicenter study involving 32,090 adult outpatients undergoing surgery/GA showed a lower incidence of PONV with sugammadex compared with neostigmine (17.2% vs. 19.6%; P < 0.001). Compared with neostigmine, sugammadex use was associated with a lower risk of PONV (OR = 0.91; 95% CI, 0.84–0.98; P = 0.014) (Azimaraghi et al. 2023). PONV prediction models and impact scores There are many predictive models for PONV. The PONV scoring system developed by Koivuranta et al. (1997) and Apfel et al. (1998), has been recognized by many researchers. Among these, Apfel simplified risk score appears to have gained the highest acceptance, and includes four major risk factors: female gender, motion sickness or history of PONV, nonsmoking status, and postoperative opioid use (Apfel et al. 1999). In this predictive model, individual risk factors are weighted equally (1 point per factor, maximum 4 points). A graded association was evident between total scores and estimated emetic outcomes: 0 points (10% risk), 1 (20%), 2 (40%), 3 (60%), and 4 points (80%), corresponding to progressively increasing PONV probabilities, with patients having scores of 0–1, 2, or ≥ 3 being classified as "low", "medium", and "high" risk, respectively. In recent years, with the development of artificial intelligence in the medical field, researchers have begun using artificial intelligence algorithms to predict early PONV (Zhou et al. 2023a), although this approach still in the exploration stage, and may prove to be of great significance in the the prevention and treatment of PONV. In clinical work, Numeric Rating Scale (NRS) or Visual Analogue Scale (VAS) are usually employed to quantify the intensity of subjective experiences, both are widely utilized in PONV studies. However, their sensitivity to reflect the minimum clinically significant difference is insufficient (Revicki et al. 2006; Cepeda et al. 2003). Therefore, Myles and Wengritzky (2012) designed a simplified PONV Impact scale, which quantifies the effects of interventions from the perspective of patients and can be utilized to identify patients at risk of clinically significant PONV. Prevention and treatment of PONV Drugs for PONV prevention and treatment There are numerous drugs available for the treatment of PONV, which can be categorized based on their mechanisms of action into 5-HT3 receptor antagonists, NK1 receptor antagonists, glucocorticoids, dopamine receptor antagonists, anticholinergics, and antihistamines. 5-HT3 receptor antagonists The 5-HT receptor family consists of seven types of receptors, among which the 5-HT3 receptor is considered to play a primary role in inducing vomiting (Johnston et al. 2014). As ligand-gated ion channels, activation of 5-HT3 receptors induces excitatory postsynaptic potentials and rapid depolarization of serotonergic neurons, triggering a rapid influx of Ca2⁺ ions (Zhu et al. 2020). This intracellular calcium surge mediates the release of emetogenic neurotransmitters and/or peptides (e.g., dopamine, cholecystokinin), substance P, glutamate, acetylcholine, or 5-HT itself (Faerber et al. 2007). As the predominant 5-HT3 receptor antagonist with the largest evidence base, ondansetron remains the pharmacological cornerstone for PONV prophylaxis and treatment (Tricco et al. 2015), although the possible understatement of either rebound PONV or breakthrough PONV may render ondansetron instead as a drug of concern, now that palonosetron no longer retains patent protection (Apfel et al. n.d.). Additionally, there are other 5-HT3 receptor antagonists such as dolasetron, granisetron, tropisetron, etc. The second-generation 5-HT3 receptor antagonist palonosetron, however, stands out, in that it exhibits a half-life of 40 hours, features positive synergism, allosteric binding, receptor internalization and partial co-antagonism against NK1 receptors (Rojas et al. 2008, 2014). Palonosetron demonstrates efficacy in preventing both acute and delayed vomiting (Rojas et al. 2014), and multiple studies have found it to be more effective than dexamethasone and other legacy 5-HT3 receptor antagonists in the prevention of PONV (Singh et al. 2016; Xiong et al. 2015; Li et al. 2015a). Research shows that compared to ramosetron, palonosetron reduces postoperative 24-hour vomiting risk by 46.5% (Number needed to treat [NNT]=6.7)‌; versus granisetron, palonosetron exhibits superior early vomiting prevention with a 71.5% risk reduction and 2.95-fold higher complete response rate‌; relative to ondansetron, palonosetron decreases early vomiting incidence by 48.3% (NNT=2.47), reduces 24-hour vomiting risk by 46.2%, and achieves 1.94-fold higher complete response rate‌ (Rojas et al. 2014). Although palonosetron shares similar potential adverse reactions with other 5-HT3 receptor antagonists—including headache, dizziness, constipation, tachycardia, QTc prolongation, and serotonin syndrome—it is considered to present no clinically relevant risk of QTc interval prolongation‌ (Apfel and Jukar-Rao 2012). In contrast, ondansetron has been issued a black box warning by the U.S. Food and Drug Administration (FDA) ‌regarding‌ risks associated with QTc prolongation and serious cardiac complications. Consequently, palonosetron may offer both superior efficacy and enhanced safety relative to ondansetron. NK1 receptor antagonists NK1 receptors are present in central and peripheral regions involved in emesis (Darmani And Ray 2009; Saito et al. 2003). Substance P, an endogenous ligand of NK1 receptor, is a key mediator of vomiting (Darmani And Ray 2009). NK1 receptor antagonists exert an antiemetic effect by competitively binding to NK1 receptors. Aprepitant, a representative drug of NK1 receptor antagonists, is often used to prevent and treat vomiting caused by highly emetogenic chemotherapy (Ibrahim et al. 2024). Clinical studies have shown that NK1 receptor antagonists are also effective against PONV (Weibel et al. 2020). In a controlled study involving 922 patients undergoing abdominal surgery, the complete remission rates of aprepitant (40 mg or 125 mg) and ondansetron at 24 h post-operation showed non-inferiority (63–64% vs 55%); in terms of the rate of no vomiting, aprepitant was significantly superior to ondansetron at 0–24 h (84–86% vs 71%) and 0–48 h (82–85% vs 66%), and its effect in controlling nausea was also better (Diemunsch et al. 2007). The latest guidelines for PONV management recommend administering aprepitant 40 mg orally before induction of anesthesia (Gan et al. 2020). Glucocorticoids Glucocorticoids have long been a mainstay in the prophylaxis and management of perioperative PONV, and their mechanism of action may be related to inhibiting the release of inflammatory mediators and directly acting on the vomiting center. The main drugs include dexamethasone and methylprednisolone, with recommended doses being 4–8 mg of dexamethasone or 40 mg of methylprednisolone via intravenous injection (Gan et al. 2020). In addition to its prophylactic effect on PONV, intraoperative dexamethasone may also improve postoperative acute pain management (Corcoran et al. 2023) without increasing the risk of surgical site infection (Corcoran et al. 2021a; Jørgensen et al. 2017) and elevated blood sugar levels (Corcoran et al. 2021b). Dopamine receptor antagonists A large number of animal studies have shown that dopamine D2 and D3 receptors are involved in the mediation of vomiting (Belkacemi And Darmani 2020). Clinically used dopamine D2-like receptor antagonists are categorized into three groups: butylbenzenes (e.g., droperidol, haloperidol), phenothiazines (e.g., chlorpromazine), and benzamides (e.g., amisulpride) can be used to prevent vomiting caused by multiple emetic stimuli or as rescue antiemetics in patients who have not responded to preventive measures (Zhong et al. 2021). Common doses are haloperidol 0.5–2.5 mg (3–4 h duration), droperidol 0.625–1.25 mg (United States Food and Drug Administration Black Box warning), amisulpride 5–10 mg (still under patent protection). It should be noted that excessive use may lead to excessive sedation and extrapyramidal reactions (such as acute dystonia, akathisia, etc.). For patients with Parkinson's disease and women in the early stages of pregnancy, it should be used with caution and avoid combining with alcohol or other central inhibitory agents. Recent observational work has used non-sedating oral perphenazine (before surgery) as the non-sedating antidopaminergic of choice, with it having a safe profile in large observational studies, and being no longer subject to patent protection (Belkacemi And Darmani 2020; Williams et al. 2021; Henao et al. 2014; Williams et al. 2011). Anticholinergics Acetylcholine, an emetic neurotransmitter, can induce vomiting, while clinically used drugs that block its metabolism may also cause vomiting (Li et al. 2015b). Anticholinergic drugs can antagonize muscarinic receptors and inhibit the release of acetylcholine. Currently available anticholinergic drugs, including scopolamine and penehyclidine, are commonly used to prevent nausea and vomiting induced by motion sickness. Additionally, both transdermal scopolamine (Pergolizzi et al. 2012) and penehyclidine (Zhao et al. 2024) have also demonstrated efficacy in managing PONV. Although anticholinergic drugs are highly effective in controlling vomiting, their adverse reactions and contraindications require careful clinical attention. Common side effects include central nervous system effects such as scopolamine-induced drowsiness and disorientation (potentially progressing to delirium in elderly patients). Anticholinergic reactions in the digestive and genitourinary systems: profound dry mouth, urinary retention, and constipation that may escalate to paralytic ileus, in severe cases. Cardiovascular risks include increased incidence of sinus tachycardia. Special population considerations include contraindication in glaucoma patients (due to intraocular pressure elevation) and cautious use in those with enlarged prostates (risk of urinary difficulty exacerbation). Furthermore, the network meta-analysis conducted by Weibel (Aveline et al. 2006) et al. demonstrates scopolamine cancelling antiemetic benefits from co-administered aprepitant and from co-administered antidopaminergics, which impairs multimodal prevention efforts. Antihistamines The physiological effects of histamine are mediated by four types of histamine receptors (Parsons And Ganellin 2006), with the activation of histamine H1 receptors in the brainstem being the main cause of motion sickness-induced vomiting (Chen et al. 2018). Histamine H1 receptor antagonists such as promethazine and diphenhydramine, are commonly used to treat motion sickness-induced nausea and vomiting (Zhong et al. 2021)。However, their monotherapeutic application in the prophylactic and therapeutic management of PONV remains limited in current clinical practice. Meanwhile, recent observational studies incorporating low-dose diphenhydramine (12.5–20 mg IV) appear promising in multimodal antiemetic prophylaxis contexts (Williams et al. (n.d.a) b, c, d), understanding that low-dose diphenhydramine may need to partially replace other sedation-inducing drugs with possibly less-profound antiemetic benefit (e.g., dexmedetomidine). It is difficult to determine whether the associated multimodal success with diphenhydramine may be related to not only antihistamine effects, but also to mild anticholinergic benefits that do not cross over into anticholinergic side effects (such as those from scopolamine) at the described dose range above, particularly when given before surgery, as reported by one author group (Williams et al.) recently in succession (Williams et al. (n.d.a) c, d). Non-pharmacological prevention and treatment of PONV The non-pharmacological prevention and treatment of PONV is mainly acupuncture and acupoint stimulation from traditional Chinese medicine. The mechanisms may include release of endogenous β-endorphin (Acar 2016), activation of adrenergic and noradrenergic nerve fibers (Stoicea et al. 2015), improvement of gastrointestinal function through bidirectional regulation (Chen et al. 2015) and reduced the use of opioids (Liu et al. 2015). A meta-analysis based on 14 randomized controlled trials (involving 1653 participants) showed that compared with the control group, transcutaneous electrical acupoint stimulation (TEAS) reduced the incidence of PONV (relative risk [RR] 0.54, 95% confidence interval [CI] 0.42—0.68), in terms of postoperative vomiting (RR 0.59, 95% CI 0.49—0.71), postoperative nausea (RR 0.46, 95% CI 0.33—0.65), and the number of patients requiring antiemetic rescue decreased (RR 0.56, 95% CI 0.40—0.78) (Freedman and O'Hara 2008).In addition, aromatherapy (Asay et al. 2019; Amirhosseini et al. 2020) and intraoperative Goal-directed Fluid Therapy (Demirel et al. 2018) can also reduce the occurrence of PONV. PONV prevention and treatment strategies Existing evidence demonstrates that conventional antiemetic interventions achieve an approximate 30% reduction in PONV risk (Apfel et al. 2004). Given a baseline incidence rate of 30%, this translates to persistent symptoms in roughly 21% of patients despite single-agent prophylactic treatment. Therefore, a single measure is (i insufficient to eliminate PONV, especially in high-risk individuals, (ii) may not significantly reduce the risk, and (iii) may be grounds to rethink the clinical values of current risk factor guidelines due to insufficient sensitivity and/or specificity. The 2020 management consensus guidelines had recommended a combination of two drugs for low and medium risk PONV patients, including 5-HT receptor antagonists and dexamethasone, and had suggested using three or four drug prophylaxis in conjunction with preventive measures such as total intravenous anesthesia for high-risk patients (Gan et al. 2020). 5-HT3 receptor antagonists are the first-line treatment for patients who have not received PONV prophylaxis (Gan et al. 2020). Considering that re-use of the same class of antiemetics used for prophylaxis may not provide additional benefit, a different class of antiemetics has been traditionally recommended for rescue therapy in patients who did not respond to PONV prophylaxis. Intravenous formulations should be preferred in patients with frequent vomiting (Gan et al. 2020), rendering oral agents proposed in recent observational work aprepitant and perphenazine as valuable for prophylaxis, but dubious for rescue. In the United States, the only antiemetic approved for PONV rescue treatment after prophylaxis failure is the dopamine D2 receptor antagonist amisulpride at a dose of 10 mg (Williams et al. (n.d.a) b; Schumacher et al. (n.d.)). Conclusions PONV represents a multifactorial complication with intricate pathophysiological mechanisms. While the Apfel scoring system is widely used and remains an important scholarly product in the history of PONV prophylaxis, its clinical/pragmatic applications face limitations, including over-reliance on subjective judgment by some practitioners, leading to inadequate assessment of factors such asrace/ethnicity, recurring opioid exposure risks, concerns regarding ondansetron and rebound nausea (or breakthough nausea)menstrual cycle fluctuations, and perioperative anxiety states, among other interacting factors. Implementation of multimodal prevention strategies remain suboptimal, particularly in primary care settings or particularly when ondansetron is used as the 5-HT3 antagonist of choice. Furthermore, the indispensable use of volatile anesthetics and opioids seems to render PONV as a perhaps unavoidable clinical dilemma. Future advancements should focus on three key areas: (i) leveraging artificial intelligence to enhance risk prediction through multimodal data integration, (ii) developing novel biomarkers for precision medicine, and optimizing perioperative protocols. As the cornerstone of perioperative medicine, anesthesiology as a medical specialty may do well to adopt a more inclusive and comprehensive risk identification approach encompassing either enhancing or abandoning traditional preoperative risk stratification, adjusting intraoperative multimodal intervention to preoperative, and postoperative personalized management. Such a strategy would systematically aim to reduce PONV incidence, to guideline-recommended levels, in the good-faith effort to substantially improve patient recovery outcomes, and to provide an important clinical advance in compassionate care, pending results generated by artificial intelligence and/or machine learning in this overdue realm.